Preview

Пульмонология

Расширенный поиск

Применение антагониста лейкотриеновых рецепторов монтелукаста для лечения бронхиальной астмы у детей первых лет жизни

https://doi.org/10.18093/0869-0189-2009-5-113-119

Полный текст:

Об авторах

Н. А. Геппе
ГОУ ВПО "Московская медицинская академия им. И.М.Сеченова"
Россия


И. М. Фарбер
ГОУ ВПО "Московская медицинская академия им. И.М.Сеченова"
Россия


Список литературы

1. Российская национальная программа "Бронхиальная астма у детей. Стратегия лечения и профилактика". М.: Изд. дом "Атмосфера"; 2008.

2. Ducharme F.M., Di Salvio F. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and / or chronic asthma in adults and children. Cochrane Database Syst. Rev. 2004; 1: CD002314.

3. Wright AL, Taussig LM. Lessons from long-term cohort studies. Childhood asthma. Eur Respir J Suppl. 1998; 27: 17S-22S

4. Busse W.W. The role of leukotrienes in asthma and allergic rhinitis. Clin. Exp. Allergy 1996; 26: 868-879.

5. Knorr B., Matz J., Bernstein J.A. et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. J. A. M. A. 1998; 279 (15): 1181-1186.

6. Knorr B., Noonan G., McBurney J. et al. Evaluation of the long-term effect of montelukast in adult (15 years) and pediatric (6- to 14-years) patients. Eur. Respir. J. 1999; 14 (suppl.): 290S.

7. Edelman J.M., Preston S.R., Turpin J.A. et al. Parent and child preference for montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in asthmatic children ages 6 to 14 years. Eur. Respir. J. 1998; 12 (suppl. 29): 25.

8. Геппе Н.А., Фарбер И.М., Малявина У.С. и др. Результаты лечения детей с бронхиальной астмой и аллергическим ринитом антагонистами лейкотриеновых рецепторов в сочетании с интервальными гипоксическими тренировками. Вопр. практ. педиатр. 2009; 3, 28-33.

9. Bisgaard H., Zielen S., GarciaGarcia M.L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 2005; 171 (4): 315-322.

10. Knorr B., Franchi L.M., Bisgaard H. et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108 (3): E48.

11. Bisgaard H., Franchi L.M., Maspero J.F. et al. Long-term safety of montelukast in 2- to 5-year old children with asthma. The World Congress on Lung Health and 10th European Respiratory Society Annual Congress, Aug. 30 - Sept. 3 2000, Florence, Italy. Eur. Respir. J. 2000; 17 (3): Abs. 2152.

12. The Childhood Asthma Management Program Research Group. Longterm effect of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 2000; 343: 1054-1063.

13. Bisgaard H., Gillies J., Groenewald M. et al. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children. Am. J. Respir. Crit. Care Med. 1999; 160: 126-131.

14. Bisgaard H., Munck S.L., Nielsen J.P. et al. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lanset. 1990; 336: 649-651.

15. Kemp J.P., Skoner D.P., Szefler S.J. et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann. Allergy Asthma Immunol. 1999; 83: 231-239.

16. Volovitz B., Duenas-Meza E., Chmielewska-Szewczyk D. et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, openlabel, crossover study in children with mild to moderate persistent asthma. Curr. Ther. Res. 2000; 61: 490-506.

17. Wowciechowska I., Duenas-Meza E., Kosa L. et al. Compliance and preference of montelukast with cromolyn in children with asthma. Allergy 1999; 54 (suppl): 25.

18. Migoya E., Kearns G.L., Hartford A. et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J. Clin. Pharmacol. May 2004; 44 (5): 487-494.

19. Van Adelsberg J., Moy J., Wei L.X. et al. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr. Med. Res. Opin. 2005; 21 (6): 971-979.

20. Bisgaard H. for the Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. 2003; 167: 379-383.

21. Bisgaard H., Garcia-Garcia M.L., Johnston S.L. et al. Montelukast reduces viralinduced asthma exacerbations: The PREVIA Study. Eur. Respir. J. 2004; 24: 212s.

22. Bisgaard H., Flores-Nunez A., Goh A. et al. Study of montelukast for the treatment of respiratory symptoms of postrespiratory syncytial virus bronchiolitis in children. Am. J. Respir. Crit. Care Med. 2008; 178 (8): 854-860.

23. Bisgaard H., Swern A., Tozzi C.A. et al. Efficacy of montelukast in patients aged 2 to 5 years with mild asthma. Eur. Respir. J. 2004; 24 (suppl. 48): #P2350.

24. Johnston N.W., Mandhane P.J., Dai J. et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120 (3): e702-е712.

25. Johnston S.L., Pattermore P.K., Sanderson G. et al. Community study of the role of viral infections in exacerbations of asthma in 9-11 year old children. Br. Med. J. 1995; 310: 1225-1229.

26. LaForce C.F., Pearlman D.S., Ruff M.E. et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann. Allergy Asthma Immunol. 2000; 85: 407-415.

27. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157: 1S-53S.

28. Bisgaard H., Malice M., Marshal J. et al. Randomized, placebo-controlled study of montelukast for treatment of post-RSV-bronchiolitic respiratory symptoms in children. Allergy 2007; 62 (suppl. 83): 127-127.

29. Robertson C.F., Henry R.L., Mellis C. et al. Short course montelukast for intermittent asthma in children: the Pre-Empt Study. In: 100th International conference American Thoracic Society, May 21-26, 2004, Orlando, Florida, USA: Abstract. Orlando; 2004. A53.

30. GINA. Global strategy for the diagnosis and management of asthma on children 5 years and younger. 2009: www.gin-asthma.org


Для цитирования:


Геппе Н.А., Фарбер И.М. Применение антагониста лейкотриеновых рецепторов монтелукаста для лечения бронхиальной астмы у детей первых лет жизни. Пульмонология. 2009;(5):113-119. https://doi.org/10.18093/0869-0189-2009-5-113-119

Просмотров: 10


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)